Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Dr Manu Vatish and Dr Sofia Cerdeira from the Nuffield Department of Women's and Reproductive Health have won a prestigious global award, that recognises teams that collaborate across disciplines and transform healthcare delivery and ultimately patient lives.

Dr Manu Vatish and Dr Sofia Cerdeira from the Nuffield Department of Women's and Reproductive Health have won a prestigious global award, that recognises teams that collaborate across disciplines and transform healthcare delivery and ultimately patient lives.

The annual UNIVANTS of Healthcare Excellence Award was given to credit the working partnership between Roche Diagnostics, Oxford University Hospitals NHS Foundation Trust and Oxford Academic Health Science Network. Their joint expertise resulted in a new test which predicts with much greater accuracy, whether a pregnant woman will develop Pre-eclampsia (PE) within the following seven days.

Pre- eclampsia is a hypertensive disorder of pregnancy, affecting 4-8% of women globally, causing major maternal and fetal morbidity. Roughly half of patients who are admitted to the hospital at risk of PE don’t end up suffering from the condition. Significant resources are used trying to identify PE mothers by measuring blood pressure and proteinuria. This is sub-optimal because these clinical signs have poor diagnostic accuracy, which means clinicians rely on clinical instinct.

“If you don’t have a firm diagnosis, you either incorrectly send someone with Pre-eclampsia home or incorrectly admit someone who doesn’t have Pre-eclampsia,” Vatish said. “Those are both bad outcomes for the professionals involved in their care.” 

Dr Manu Vatish, Dr Sofia Cerdeira and Dr Tim James (Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust) worked extensively around the potential use of laboratory tests that could offer clinicians reassurance of their PE diagnosis while avoiding hospitalization of patients who won’t develop the condition. They found significant opportunity in two angiogenic biomarkers: Placental Growth Factor (PlGF), and its receptor, Soluble Flt-1. These biomarkers showed a very powerful negative predictive value, meaning they were a reliable indicator of patients who were not likely to develop PE.

The test was developed by Roche Diagnostics and a clinical trial was run at the John Radcliffe Hospital (Oxford University Hospitals NHS Foundation Trust). Following improved patient outcomes, the Oxford Academic Health Science Network launched the test to other maternity units across the UK. It has been well-received by patients, who are often unnecessarily frightened when PE is explained to them during prenatal visits. Hospitalization can be a frustrating experience for patients who ultimately have their baby without issue.

This high profile award attracted 300 applications from 97 countries. It is a fantastic acknowledgment of how shared expertise across disciplines, including the core laboratory, can reshape care pathways and ultimately achieve better outcomes for patients, clinicians, payers and entire health systems. 

 

Latest news

Mitox 2020 bookings open

MitOX 2020 Bookings open

The Nuffield Department of Women's & Reproductive Health invites you to MitOX 2020 on Friday 3rd April 2020 in Oxford. It's our annual meeting packed with short talks and posters on cancer metabolism, neuroscience, diabetes, mitochondrial disorders and general mitochondrial biology.

How do unborn babies and mothers communicate via the placenta

How do unborn babies and mothers communicate via the placenta?

DPhil student Neva Kandzija wins an Oxford Sparks competition to have her Placenta research transformed into a two minute animation film for free.

Understanding the origins of ovarian cancer

Understanding the origins of ovarian cancer

Research into the early detection of ovarian cancer by the Ahmed group, receives a boost thanks to a gift of £43,000 from the Dianne Oxberry Trust.

100 000 babies screened for increased type 1 diabetes risk in the ingr1d study

100 000 babies screened for increased type 1 diabetes risk in the INGR1D Study

Celebrating a major milestone for one of Europe’s biggest type 1 diabetes research cooperations: The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has successfully screened 100,000 newborns across Europe (including over 7500 newborns in the Thames Valley) for an increased genetic risk of developing type 1 diabetes.